Recursion Pharmaceuticals, Inc.(RXRX)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RXRX Recursion Pharmaceuticals, Inc.

交易中 07-08 10:34:17 EDT

5.52

+0.59

+11.97%

最高5.55	最低5.00	成交量1,763万
今开5.01	昨收4.93	日振幅11.16%
总市值22.46亿	流通市值21.45亿	总股本4.07亿
成交额9,320万	换手率4.54%	流通股本3.89亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RXRX","market":"US","secType":"STK","nameCN":"Recursion Pharmaceuticals, Inc.","latestPrice":5.52,"timestamp":1751985256902,"preClose":4.93,"halted":0,"volume":17628006,"delay":0,"floatShares":388511287,"shares":406916486,"eps":-1.819511,"marketStatus":"交易中","change":0.59,"latestTime":"07-08 10:34:17 EDT","open":5.005,"high":5.55,"low":5,"amount":93199860.0230016,"amplitude":0.111562,"askPrice":5.53,"askSize":5400,"bidPrice":5.52,"bidSize":6010,"shortable":3,"etf":0,"ttmEps":-1.819511,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1752004800000},"marketStatusCode":2,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":4.93,"preHourTrading":{"tag":"盘前","latestPrice":5.01,"preClose":4.93,"latestTime":"09:29 EDT","volume":337175,"amount":1677833.8820125002,"timestamp":1751981399999},"postHourTrading":{"tag":"盘后","latestPrice":4.93,"preClose":4.93,"latestTime":"19:59 EDT","volume":434508,"amount":2142976.8821,"timestamp":1751932799998},"volumeRatio":3.70271,"impliedVol":0.9459,"impliedVolPercentile":0.632},"requestUrl":"/m/hq/s/RXRX/wiki","defaultTab":"wiki","newsList":[{"id":"2549525580","title":"Strategic Acquisition and Market Positioning Drive Buy Rating for Recursion Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2549525580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549525580?lang=zh_cn&edition=full","pubTime":"2025-07-08 22:15","pubTimestamp":1751984118,"startTime":"0","endTime":"0","summary":"In a report released today, Gil Blum from Needham maintained a Buy rating on Recursion Pharmaceuticals, with a price target of $8.00. Gil Blum has ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-acquisition-and-market-positioning-drive-buy-rating-for-recursion-pharmaceuticals-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"战略收购和市场定位推动递归制药买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-acquisition-and-market-positioning-drive-buy-rating-for-recursion-pharmaceuticals-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RXRX"],"gpt_icon":0},{"id":"2549540746","title":"Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2549540746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549540746?lang=zh_cn&edition=full","pubTime":"2025-07-08 21:12","pubTimestamp":1751980334,"startTime":"0","endTime":"0","summary":"Rallybio stock soared on Tuesday after the company reached an agreement with Recursion Pharmaceuticals.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/rallybio-stock-rlyb-rockets-25-on-a-recursion-pharmaceuticals-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"Rallybio股价(RLYB)因Recursion Pharmaceuticals协议而飙升25%","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/rallybio-stock-rlyb-rockets-25-on-a-recursion-pharmaceuticals-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RLYB","BK4539","RXRX","BK4609","BK4548","BK4139","BK4611"],"gpt_icon":0},{"id":"2549347547","title":"Recursion Pharmaceuticals Acquires ENPP1 Inhibitor Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2549347547","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549347547?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:45","pubTimestamp":1751978704,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals ( ($RXRX) ) just unveiled an announcement. On July 8, 2025, Recursion Pharmaceuticals acquired full ownership of the ENPP...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-acquires-enpp1-inhibitor-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"Recursion制药公司收购ENPP1抑制剂项目","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/recursion-pharmaceuticals-acquires-enpp1-inhibitor-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4609","RXRX","BK4548","BK4611","BK4139","BK4539"],"gpt_icon":0},{"id":"2549544605","title":"Rallybio Corporation Divests Interest in REV102 Program to Recursion Pharmaceuticals for Up to $25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544605","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544605?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976038,"startTime":"0","endTime":"0","summary":"Rallybio Corporation has announced the sale of its interest in the REV102 program to Recursion Pharmaceuticals, a move anticipated to extend Rallybio's cash runway to mid-2027. The deal, valued at up to $25 million, includes an upfront equity payment of $7.5 million and additional milestone payments. The REV102 program, focused on developing an ENPP1 inhibitor for treating hypophosphatasia , originated from a joint venture between the two companies. Rallybio's CEO, Stephen Uden, expressed enthusiasm for the program's progression, highlighting the collaboration's success in advancing a potential oral disease-modifying treatment for HPP.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content us","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Rallybio Corporation以高达2500万美元的价格将REV102项目的权益剥离给Recursion Pharmaceuticals","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL1rRsmK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","RXRX","RLYB","BK4548","BK4611","BK4139","BK4539"],"gpt_icon":1},{"id":"2549645544","title":"Recursion Pharmaceuticals Announces Acquisition of Full Rights to REV102, Aiming to Launch First Oral Therapy for Hypophosphatasia by 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2549645544","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549645544?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976034,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Announces Acquisition of Full Rights to REV102, Aiming to Launch First Oral Therapy for Hypophosphatasia by 2026. Recursion Pharmaceuticals Inc.  has announced the acquisition of Rallybio's full interest in their joint ENPP1 inhibitor program, REV102, designed for the treatment of hypophosphatasia , a rare genetic disorder. The acquisition includes an associated backup molecule. This move grants Recursion full ownership of the program, allowing the company to expedite the development of what could become the first oral disease-modifying therapy for HPP. Currently in IND-enabling studies, REV102 is expected to enter Phase 1 clinical trials in the second half of 2026. The program aims to address the underlying cause of HPP by inhibiting the enzyme ENPP1, potentially improving bone mineralization. Results of these studies have yet to be presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Recursion Pharmaceuticals宣布收购REV102的全部权利，旨在2026年前推出首个治疗低磷酸酶症的口服疗法","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL5SzTHN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB","BK4539","BK4112","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU2210149790.SGD","BK4585","BK4609","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210150020.SGD","BK4588","NDAQ","RXRX","BK4548","BK4139","BK4611"],"gpt_icon":1},{"id":"2549616544","title":"Recursion Pharmaceuticals Inc - Rallybio Eligible for $7.5 Mln Upfront and $12.5 Mln Contingent","url":"https://stock-news.laohu8.com/highlight/detail?id=2549616544","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549616544?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Recursion Pharmaceuticals Inc-RallyBio有资格获得750万美元的预付款和1250万美元的或有资金","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA7XRCDR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4139","BK4611","BK4539","RXRX","BK4609"],"gpt_icon":0},{"id":"2549544692","title":"Recursion Pharmaceuticals Inc - Rallybio to Receive Low Single-Digit Royalties on Future Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544692?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Recursion Pharmaceuticals Inc-RallyBio将在未来销售中获得低个位数特许权使用费","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA7XRCDR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","BK4609","BK4539","BK4139","RXRX","BK4548"],"gpt_icon":0},{"id":"2549544321","title":"Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral Enpp1 Inhibitor for Hypophosphatasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544321?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Recursion获得REV102的全部权利，REV102是一种治疗低磷酸酶症的潜在首创口服Enpp1抑制剂","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA7XRCDR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4609","BK4611","BK4548","BK4539","RXRX","BK4139"],"gpt_icon":0},{"id":"2549446955","title":"Recursion Pharmaceuticals Inc - REV102 Phase 1 Clinical Trials Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2549446955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549446955?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Recursion Pharmaceuticals Inc–REV102 1期临床试验预计于2026年下半年进行","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA7XRCDR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4611","RXRX","BK4609","BK4139","BK4548"],"gpt_icon":0},{"id":"2549954499","title":"Rallybio Corp - Expects Cash Runway Extension to Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2549954499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549954499?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Rallybio Corp–预计现金跑道将延长至2027年中期","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA3RGDFS:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4609","RXRX","BK4539","BK4611","RLYB","BK4139"],"gpt_icon":0},{"id":"2549544998","title":"Rallybio Corp - Sells REV102 Interest to Recursion for up to $25 Mln Including an Upfront Equity Payment of $7.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544998?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Rallybio Corp–以高达2500万美元的价格向Recursion出售REV102权益，其中包括750万美元的预付股权","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA3RGDFS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4609","RXRX","BK4539","BK4611","RLYB","BK4139"],"gpt_icon":0},{"id":"2549544995","title":"Rallybio Corp - Eligible for $7.5 Mln Upfront, $12.5 Mln Contingent Equity","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544995?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Rallybio Corp–有资格获得750万美元的预付款和1250万美元的或有股权","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA3RGDFS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4609","RLYB","BK4611","BK4548","BK4139","BK4539","RXRX"],"gpt_icon":0},{"id":"2549544960","title":"Rallybio : Expects Its Cash Runway to Extend Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2549544960","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549544960?lang=zh_cn&edition=full","pubTime":"2025-07-08 20:00","pubTimestamp":1751976001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Rallybio：预计其现金跑道将延伸至2027年中期","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA3RGDFS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","RLYB","BK4139","BK4611","BK4539","RXRX","BK4609"],"gpt_icon":0},{"id":"2549949285","title":"Recursion Pharmaceuticals, Inc.7月7日成交额为1.84亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549949285","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549949285?lang=zh_cn&edition=full","pubTime":"2025-07-08 13:26","pubTimestamp":1751952413,"startTime":"0","endTime":"0","summary":"美东时间2025年7月7日，Recursion Pharmaceuticals, Inc.成交额为1.84亿美元，成交额较昨日增加111.99%，当日成交量为3737.75万股。Recursion Pharmaceuticals, Inc.于2025年7月7日跌6.45%，报4.93美元，该股过去5个交易日跌1.99%，年初至今跌27.07%，过去60日涨24.18%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-07|1.84亿|111.99%|3737.75万|#|2025-07-03|8662.72万|-34.37%|1658.21万|#|2025-07-02|1.32亿|-33.46%|2507.21万|#|2025-07-01|1.98亿|49.31%|3801.29万|#|2025-06-30|1.33亿|-44.50%|2578.06万|Recursion Pharmaceuticals Inc是一家处于临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708132701a69c62cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4609","RXRX","BK4548","BK4611","BK4139","BK4539"],"gpt_icon":1},{"id":"2548817913","title":"Recursion Pharmaceuticals Coverage Assumed by Morgan Stanley at Equal-Weight","url":"https://stock-news.laohu8.com/highlight/detail?id=2548817913","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548817913?lang=zh_cn&edition=full","pubTime":"2025-07-04 01:56","pubTimestamp":1751565360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 03, 2025 13:56 ET (17:56 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"摩根士丹利假设等权重的递归制药覆盖范围","themeId":"a5c7723d99dafdbce5a1668ca6a8dc19","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","LU0006306889.USD","LU1162221912.USD","LU0106261372.USD","BK4539","IE00BKVL7J92.USD","LU2089284900.SGD","BK4504","LU0795875086.SGD","BK4609","LU1668664300.SGD","BK4127","LU0795875169.SGD","BK4588","LU2111349929.HKD","BK4548","LU2357305700.SGD","IE00BZ1G4Q59.USD","LU0225283273.USD","LU0912757837.SGD","LU1074936037.SGD","LU1732800096.USD","BK4585","LU2271345857.HKD","BK4516","LU1720051017.SGD","LU0267386448.USD","LU0158827948.USD","LU2133065610.SGD","LU0314104364.USD","BK4534","LU1363072403.SGD","BK4139","LU2028103732.USD","LU1720051108.HKD","BK4611","LU0158827781.USD","BK4581","LU0971096721.USD","LU2089283258.USD","LU1989772840.SGD","RXRX","LU0234570918.USD","LU0320765646.SGD","LU1548497426.USD","LU2347655156.SGD","LU0106831901.USD","LU1732799900.SGD","LU2023251221.USD","LU0098860793.USD"],"gpt_icon":0},{"id":"2548805900","title":"Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Recursion Pharmaceuticals (RXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2548805900","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548805900?lang=zh_cn&edition=full","pubTime":"2025-07-03 18:30","pubTimestamp":1751538612,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on GH Research (GHRS – Research Report) and Recursion Pharmaceutical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gh-research-ghrs-and-recursion-pharmaceuticals-rxrx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"分析师提供对医疗保健公司的见解：GH Research(GHRS)和Recursion Pharmaceuticals(RXRX)","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-gh-research-ghrs-and-recursion-pharmaceuticals-rxrx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","BK4588","BK4611","BK4609","BK4585","BK4007","BK4551","BK4548","GHRS","RXRX","BK4196","BK4539","HCSG","BK4535","GH"],"gpt_icon":0},{"id":"2548808143","title":"Recursion Pharmaceuticals assumed with an Equal Weight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2548808143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548808143?lang=zh_cn&edition=full","pubTime":"2025-07-03 17:45","pubTimestamp":1751535916,"startTime":"0","endTime":"0","summary":"Morgan Stanley assumed coverage of Recursion Pharmaceuticals (RXRX) with an Equal Weight rating and $5 price target Recursion has faced volatility ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-assumed-with-an-equal-weight-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"摩根士丹利假设递归制药公司享有同等权重","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/recursion-pharmaceuticals-assumed-with-an-equal-weight-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089284900.SGD","LU0971096721.USD","IE00BZ1G4Q59.USD","LU0225283273.USD","BK4588","LU1989772923.USD","LU1363072403.SGD","LU0098860793.USD","LU0795875086.SGD","LU0234570918.USD","LU1732800096.USD","BK4539","LU2111349929.HKD","LU0158827781.USD","BK4611","BK4548","LU0314104364.USD","LU0106261372.USD","LU1162221912.USD","BK4581","LU2023251221.USD","BK4609","LU2028103732.USD","LU1668664300.SGD","BK4127","LU2089283258.USD","LU1720051017.SGD","LU1720051108.HKD","IE00BKVL7J92.USD","LU0158827948.USD","LU0267386448.USD","LU1732799900.SGD","LU2347655156.SGD","BK4504","LU1074936037.SGD","LU1548497426.USD","RXRX","BK4534","LU0106831901.USD","LU0006306889.USD","LU0320765646.SGD","LU0795875169.SGD","LU1989772840.SGD","LU0912757837.SGD","LU2271345857.HKD","BK4516","LU2357305700.SGD","BK4585","LU2133065610.SGD","BK4139"],"gpt_icon":0},{"id":"2548182445","title":"Recursion Pharmaceuticals, Inc.7月2日成交额为1.32亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548182445","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548182445?lang=zh_cn&edition=full","pubTime":"2025-07-03 13:36","pubTimestamp":1751520977,"startTime":"0","endTime":"0","summary":"美东时间2025年7月2日，Recursion Pharmaceuticals, Inc.成交额为1.32亿美元，成交额较昨日减少33.46%，当日成交量为2507.21万股。Recursion Pharmaceuticals, Inc.于2025年7月2日涨1.56%，报5.21美元，该股过去5个交易日涨0.97%，年初至今跌22.93%，过去60日涨22.88%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-02|1.32亿|-33.46%|2507.21万|#|2025-07-01|1.98亿|49.31%|3801.29万|#|2025-06-30|1.33亿|-44.50%|2578.06万|#|2025-06-27|2.39亿|113.75%|4663.30万|#|2025-06-26|1.12亿|5.56%|2151.24万|Recursion Pharmaceuticals Inc是一家处于临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703133621a72bf75b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4609","RXRX","BK4539","BK4611","BK4139"],"gpt_icon":1},{"id":"2548326854","title":"Recursion Pharmaceuticals, Inc.7月1日成交额为1.98亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548326854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548326854?lang=zh_cn&edition=full","pubTime":"2025-07-02 13:22","pubTimestamp":1751433739,"startTime":"0","endTime":"0","summary":"美东时间2025年7月1日，Recursion Pharmaceuticals, Inc.成交额为1.98亿美元，成交额较昨日增加49.31%，当日成交量为3801.29万股。Recursion Pharmaceuticals, Inc.于2025年7月1日涨1.38%，报5.13美元，该股过去5个交易日跌1.72%，年初至今跌24.11%，过去60日涨6.65%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-01|1.98亿|49.31%|3801.29万|#|2025-06-30|1.33亿|-44.50%|2578.06万|#|2025-06-27|2.39亿|113.75%|4663.30万|#|2025-06-26|1.12亿|5.56%|2151.24万|#|2025-06-25|1.06亿|-11.33%|2093.01万|Recursion Pharmaceuticals Inc是一家处于临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702132226a729d09a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4548","BK4539","BK4609","RXRX","BK4611"],"gpt_icon":1},{"id":"2548402906","title":"Recursion Pharmaceuticals, Inc.6月30日成交额为1.33亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548402906","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548402906?lang=zh_cn&edition=full","pubTime":"2025-07-01 13:09","pubTimestamp":1751346591,"startTime":"0","endTime":"0","summary":"美东时间2025年6月30日，Recursion Pharmaceuticals, Inc.成交额为1.33亿美元，成交额较昨日减少44.50%，当日成交量为2578.06万股。Recursion Pharmaceuticals, Inc.于2025年6月30日涨0.6%，报5.06美元，该股过去5个交易日涨4.76%，年初至今跌25.15%，过去60日跌4.35%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-06-30|1.33亿|-44.50%|2578.06万|#|2025-06-27|2.39亿|113.75%|4663.30万|#|2025-06-26|1.12亿|5.56%|2151.24万|#|2025-06-25|1.06亿|-11.33%|2093.01万|#|2025-06-24|1.20亿|13.93%|2299.31万|Recursion Pharmaceuticals Inc是一家处于临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701130958a4c821bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4548","BK4539","BK4609","RXRX","BK4611"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.recursion.com","stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":-0.102},{"period":"3month","weight":0.2418},{"period":"6month","weight":-0.3209},{"period":"1year","weight":-0.3265},{"period":"ytd","weight":-0.2707}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.036},{"period":"3month","weight":0.2502},{"period":"6month","weight":0.0529},{"period":"1year","weight":0.1191},{"period":"ytd","weight":0.059}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Recursion Pharmaceuticals, Inc.最初成立于2013年11月4日，并在特拉华州注册成立 。 该公司是一家领先的临床阶段TechBio公司，将生物解码以将药物发现产业化。公司使命的核心是递归操作系统（OS），这是一个跨多种技术构建的平台，使公司能够在超过50 PB的专有数据中绘制和导航数万亿个以生物、化学和患者为中心的关系。该公司将物理和数字组件的这种集成框定为迭代循环，其中规模化的“湿实验室”生物学、化学和以患者为中心的实验数据由“干实验室”计算工具组织，以便识别、验证和翻译治疗见解。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.050758},{"month":2,"riseRate":0.5,"avgChangeRate":0.092727},{"month":3,"riseRate":0,"avgChangeRate":-0.270652},{"month":4,"riseRate":0.25,"avgChangeRate":-0.144468},{"month":5,"riseRate":0.4,"avgChangeRate":0.084296},{"month":6,"riseRate":0.6,"avgChangeRate":0.136566},{"month":7,"riseRate":0.6,"avgChangeRate":0.165738},{"month":8,"riseRate":0.25,"avgChangeRate":-0.10569},{"month":9,"riseRate":0.25,"avgChangeRate":-0.072683},{"month":10,"riseRate":0,"avgChangeRate":-0.131747},{"month":11,"riseRate":0.5,"avgChangeRate":0.076362},{"month":12,"riseRate":0.25,"avgChangeRate":0.027925}],"exchange":"NASDAQ","name":"Recursion Pharmaceuticals, Inc.","nameEN":"Recursion Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.2","shortVersion":"4.34.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Recursion Pharmaceuticals, Inc.(RXRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Recursion Pharmaceuticals, Inc.(RXRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Recursion Pharmaceuticals, Inc.,RXRX,Recursion Pharmaceuticals, Inc.股票,Recursion Pharmaceuticals, Inc.股票老虎,Recursion Pharmaceuticals, Inc.股票老虎国际,Recursion Pharmaceuticals, Inc.行情,Recursion Pharmaceuticals, Inc.股票行情,Recursion Pharmaceuticals, Inc.股价,Recursion Pharmaceuticals, Inc.股市,Recursion Pharmaceuticals, Inc.股票价格,Recursion Pharmaceuticals, Inc.股票交易,Recursion Pharmaceuticals, Inc.股票购买,Recursion Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Recursion Pharmaceuticals, Inc.(RXRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Recursion Pharmaceuticals, Inc.(RXRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况